MRSA is a havoc and difficult to treat. Options are Vancomycin, Linezolid and Teicoplanin. There is a recent study by Goldberg E etal although retrospective cohort; published ahead of print in J antimicrob Chemother. 2010 May 27, PMID: 20507860.
"Co-trimoxazole versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia: a retrospective cohort study."
It explores the role of Co-trimoxazole in MRSA. Its showed that co-trimoxazole had a safety and efficacy profile similar to that of vancomycin and may offer an attractive additional therapeutic option for MRSA bacteraemia with further prospective trials required.
This means with increasing resistance to higher antibiotics, the sensitivity pattern is moving to the class of antibiotics which are not in much use. This nonexposure to these antibiotics reduce the selection of bacteria hence resistance against that antibiotic.
